Analytical Data
-
Gene name
AKT3
- Application
-
Alternative Names
AKT3；PKBG；RAC-gamma serine/threonine-Protein kinase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y243
-
Expression Region
1-479aa
-
AA Sequence
MSDVTIVKEGWVQKRGKYIKNWRPRYFLLKTDGSFIGYKEKPQDVDLPYP LNNFSVAKCQLMKTERPKPNTFIIRCLQWTTVIERTFHVDTPEEREEWTE AIQAVADRLQRQEEERMNCSPTSQIDNIGEEEMDASTTHHKRKTMNDFDY LKLLGKGTFGKVILVREKASGKYYAMKILKKEVIIAKDEVAHTLTESRVL KNTRHPFLTSLKYSFQTKDRLCFVMEYVNGGELFFHLSRERVFSEDRTRF YGAEIVSALDYLHSGKIVYRDLKLENLMLDKDGHIKITDFGLCKEGITDA ATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQD HEKLFELILMEDIKFPRTLSSDAKSLLSGLLIKDPNKRLGGGPDDAKEIM RHSFFSGVNWQDVYDKKLVPPFKPQVTSETDTRYFDEEFTAQTITITPPE KYDEDGMDCMDNERRPHFPQFSYSASGRE
-
Molecular Weight
83 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AKT3, a member of the AKT family of serine/threonine kinases, plays a crucial role in various cellular processes, including cell growth, proliferation, survival, and metabolism. Its dysregulation has been implicated in a variety of diseases, particularly cancer and neurological disorders. Research into AKT3 has gained momentum with the growing understanding of its role in the phosphoinositide 3-kinase (PI3K) signaling pathway, which is often activated in malignancies. The recombinant production of AKT3 protein has become pivotal for studying its biological functions, interactions, and potential as a therapeutic target. Utilizing techniques such as recombinant DNA technology, scientists can produce significant quantities of AKT3 for in vitro studies, allowing for detailed investigations into its enzymatic activity, substrate specificity, and effects on downstream signaling pathways. Furthermore, these studies can help elucidate the molecular mechanisms by which AKT3 contributes to tumorigenesis and neurodevelopmental processes. As a result, understanding the properties of recombinant AKT3 is essential not only for basic research but also for developing targeted therapies that aim to inhibit its activity in diseases where it is overactive. Consequently, the exploration of AKT3 as a therapeutic target offers promising avenues for novel treatments in oncology and beyond, highlighting the importance of obtaining and characterizing the recombinant protein for future studies.
